Print
Email
Print Edition StoriesThursday, January 14, 2010
Hepregen reels in $500k SBIR award
By Mass High Tech staff
Funding drugs for rare diseases
MHT's Julie Donnelly: Life science startups finding investments
MHT's Efrain Viscarolasaga: Tech companies may have to wait for stimulus funds
Hepregen Corp. has won a $500,000 Phase 2 SBIR grant from the National Science Foundation, contributing to the company’s total $2 million in federal funding.
The Medford-based company is developing a platform to reduce the liver toxicity caused by approved drugs. The SBIR grant funds will be used on a project, “Development of a Human Liver Platform for High-Throughput Screening of Drug-Induced Liver Injury and Drug-Drug Interaction”, led by director of research Salman Khetani
The platform is based on technology developed by 2009 Mass High Tech Woman to Watch Sangeeta Bhatia, a professor in the Harvard-MIT Division of Health Sciences and Technology and MIT’s Department of Electrical Engineering and Computer Science. The technology is based on engineered “miniature micro liver cells.”
Hepregen was co-founded in 2007 by Bhatia, Khetani, and Bernadette Fendrock, president and CEO of the company.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
